Latest & greatest articles for pantoprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pantoprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pantoprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pantoprazole

1. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. (Abstract)

Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. The aim of this study is to evaluate the preventive effect of proton pump inhibitors on gastrointestinal (GI) bleeding in patients with acute coronary syndromes (ACS) who are at high risk for GI bleeding.We enrolled 665 patients with ACS who had one or more of the following risk factors for GI bleeding: 75 years of age or older, history of peptic ulcer disease, history of GI (...) bleeding, cardiogenic shock, and chronic renal dysfunction (serum creatinine, >2 mg/dL). Patients were randomly assigned to receive 40 mg of pantoprazole or placebo twice daily for 7 days, in addition to standard treatment of ACS. The primary end point was the occurrence of GI bleeding during hospitalization.During a median time of hospitalization of 12 days, 12 (3.6%) of 332 patients in the placebo group had an occurrence of GI bleeding, as compared with 4 (1.2%) of the 333 patients

2011 Journal of critical care Controlled trial quality: uncertain

2. Pantoprazole

Pantoprazole Top results for pantoprazole - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pantoprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

3. Comparison of Intravenous plus Oral Pantoprazole Therapy and Oral Pantoprazole Alone for Preventing Gastrointestinal Bleeding in Acute Coronary Syndrome Patients with High Bleeding Risk. (Abstract)

Comparison of Intravenous plus Oral Pantoprazole Therapy and Oral Pantoprazole Alone for Preventing Gastrointestinal Bleeding in Acute Coronary Syndrome Patients with High Bleeding Risk. It is unclear whether intravenous proton pump inhibition is more effective than oral administration in preventing gastrointestinal (GI) bleeding in high bleeding risk patients with acute coronary syndromes (ACS).A total of 504 patients with ACS and high bleeding risk were randomly assigned into two groups (...) . Study group (n=252) received intravenous pantoprazole for five days and subsequent oral pantoprazole for 12 months. Control group (n=252) received oral pantoprazole for 12 months. Major adverse cardiac events (death, re-infarction, re-revascularisation and stroke) and GI bleeding were registered after a follow-up of 12 months. No statistically significant differences were found in the major adverse cardiac events between the two groups after the follow-up (p >0.05). The incidence of major GI

2015 Heart, lung & circulation Controlled trial quality: uncertain

4. Continuous versus Intermittent Intravenous Pantoprazole for Acute Gastrointestinal Bleeding

Continuous versus Intermittent Intravenous Pantoprazole for Acute Gastrointestinal Bleeding Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) Intravenous Pantoprazole for Acute Gastrointestinal Bleeding: A Review of the Clinical Effectiveness and Guidelines DATE: 01 May 2015 CONTEXT AND POLICY ISSUES The gastrointestinal (GI) tract stretches from the mouth to the anus and gastrointestinal bleeding describes any bleeding that starts in the GI tract. Acute GI bleeding refers to the passage of a clinically significant amount of blood (i.e., the passage of more than a scant amount of blood) 1 Acute bleeding in the upper part of the GI tract often

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)

Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01735227 Recruitment Status : Unknown Verified November 2012 by Yaling Han, Shenyang Northern Hospital. Recruitment status was: Not yet recruiting First

2012 Clinical Trials

6. Controloc Control - pantoprazole

Controloc Control - pantoprazole European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. London, 8 May 2009 Doc.Ref.: EMEA/374215/2009 ASSESSMENT REPORT FOR CONTROLOC Control International Nonproprietary Name: pantoprazole Procedure (...) of heartburn is universal and that it is in patients’ interest across the community to allow access to a harmonised non- prescription pantoprazole product. In addition, it would give Community-wide access and consumer protection, based on harmonised labelling and avoid diverted markets. The legal basis for this application refers to Article 10(3) of Directive 2001/83/EC, as amended – hybrid application. The chosen reference product is: Reference medicinal product which is or has been authorised

2009 European Medicines Agency - EPARs

7. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

2001 DARE.

8. "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-

"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER- "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER- - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER- (dOPPLER) The safety and scientific validity of this study

2014 Clinical Trials

9. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. (Abstract)

Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Proton pump inhibitors (PPIs) are usually prescribed to patients undergoing dual antiplatelet therapy to decrease the risk of gastrointestinal bleeding. Recent studies have raised concerns that PPIs could reduce clopidogrel's efficacy by competitive inhibition of cytochrome P450 2C19 (...) isoenzyme. All PPIs are metabolized by cytochrome P450 2C19, although to varying degrees, and according to in-vitro studies, pantoprazole is the weakest inhibitor of this isoenzyme. We hypothesized that this drug interaction might not be a class effect.One month after an acute myocardial infarction 34 consecutive patients undergoing dual antiplatelet therapy were prospectively analyzed. Platelet function was measured (VerifyNow system), in each patient, in three consecutive clinical scenarios: (i) first

2011 European journal of gastroenterology & hepatology Controlled trial quality: uncertain

10. Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis

Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00839488 Recruitment Status : Terminated (the chief of GS left the hopsital and the successor did't want to keep on this study) First Posted : February 9

2009 Clinical Trials

11. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. (Abstract)

Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Limited data on proton pump inhibitors in infants led regulatory agencies to request sponsors to conduct pediatric studies.To determine the pharmacodynamic response to pantoprazole in infants with GERD to aid the dose selection for an efficacy study.In two open-label studies, neonates and preterm infants (study 1, ~1.2 mg/kg (...) [high dose]) and infants 1 through 11 months (study 2, ~0.6 [low dose] or ~1.2 mg/kg [high dose]) received once-daily pantoprazole. Twenty-four-hour dual-electrode pH-metry parameters were compared between predose and steady state (≥5 days) (two-sided paired t test). Treatment was administered for ≤6 weeks.In studies 1 and 2, 21 and 24 patients, respectively, were enrolled for pharmacodynamic evaluation. The high dose provided similar responses in the two studies and improved these parameters

2011 Digestive diseases and sciences Controlled trial quality: uncertain

12. Comparison of Pantoprazole and Ranitidine in Dyspepsia

Comparison of Pantoprazole and Ranitidine in Dyspepsia Comparison of Pantoprazole and Ranitidine in Dyspepsia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparison of Pantoprazole and Ranitidine (...) Details Study Description Go to Brief Summary: The H0 hypothesis of the study is there is no difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department. The H1 hypothesis is there is difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department. Condition or disease Intervention/treatment Phase Dyspepsia Drug: Pantoprazole Drug: Ranitidine Phase 4 Detailed Description: Dyspepsia

2012 Clinical Trials

13. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial Full Text available with Trip Pro

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial Antiplatelets and anticoagulants are associated with increased upper gastrointestinal bleeding. We evaluated whether proton pump inhibitor therapy could reduce this risk.We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants with stable cardiovascular disease and peripheral artery disease. Participants were randomly (...) assigned to groups given pantoprazole 40 mg daily or placebo, as well as rivaroxaban 2.5 mg twice daily with aspirin 100 mg once daily, rivaroxaban 5 mg twice daily, or aspirin 100 mg alone. The primary outcome was time to first upper gastrointestinal event, defined as a composite of overt bleeding, upper gastrointestinal bleeding from a gastroduodenal lesion or of unknown origin, occult bleeding, symptomatic gastroduodenal ulcer or ≥5 erosions, upper gastrointestinal obstruction, or perforation.There

2019 EvidenceUpdates

14. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions

Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Kaplan G G, Bates D, McDonald D, Panaccione R, Romagnuolo J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of an intravenous proton pump inhibitor (IV PPI), pantoprazole, in patients with upper gastrointestinal bleeding (UGIB) or patients receiving nil by mouth (NPO). In connection to this, the study examined the use of a multidisciplinary intervention to reduce inappropriate use of IV PPI. This intervention had four

2005 NHS Economic Evaluation Database.

15. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding

Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Wang J, Yang K, Ma B, Tian J, Liu Y, Bai Z, Jiang L, Sun S, Li J, Liu R, Hao X, He X CRD summary The authors concluded that intravenous pantoprazole (...) administered after endoscopic treatment reduces ulcer re-bleeding, surgical intervention, and length of hospital stay, but not mortality nor blood transfusions. This was a generally well-conducted review and the findings for the overall analyses are likely to be reliable. Authors' objectives To evaluate the effectiveness of intravenous pantoprazole as an additional treatment following successful endoscopic haemostasis of peptic ulcer bleeding. Searching The Cochrane Central Register of Controlled Trials

2009 DARE.

16. Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding

Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02108756 Recruitment Status : Unknown Verified April 2014 by Chia Tai Tianqing Pharmaceutical Group Co

2014 Clinical Trials

17. Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding

Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Esomeprazole Versus (...) Pantoprazole to Prevent Peptic Ulcer Rebleeding The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00881413 Recruitment Status : Withdrawn (problems in funding) First Posted : April 15, 2009 Last Update Posted : April 8, 2015 Sponsor: Lotung Poh-Ai Hospital Collaborator: Tomorrow Medical Foundation Information

2009 Clinical Trials

18. Pantoprazole-induced acute interstitial nephritis Full Text available with Trip Pro

Pantoprazole-induced acute interstitial nephritis 23109611 2013 03 04 2018 12 02 1488-2329 185 1 2013 Jan 08 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Pantoprazole-induced acute interstitial nephritis. 56-9 10.1503/cmaj.120954 Klassen Sheila S Department of Medicine, McMaster University, Hamilton, Ont., Canada. sheila.liu.klassen@gmail.com Krepinsky Joan C JC Prebtani Ally P H AP eng Case Reports Journal Article Research Support, Non-U.S (...) . Gov't 2012 10 29 Canada CMAJ 9711805 0820-3946 0 2-Pyridinylmethylsulfinylbenzimidazoles 0 Proton Pump Inhibitors AYI8EX34EU Creatinine D8TST4O562 Pantoprazole AIM IM CMAJ. 2013 Jul 9;185(10):899 23836921 2-Pyridinylmethylsulfinylbenzimidazoles adverse effects Aged Creatinine blood Humans Kidney drug effects pathology Male Nephritis, Interstitial blood chemically induced diagnosis pathology Pantoprazole Proton Pump Inhibitors adverse effects 2012 10 31 6 0 2012 10 31 6 0 2013 3 5 6 0 ppublish

2013 CMAJ : Canadian Medical Association Journal

19. High Dose versus Low Dose Intravenous Pantoprazole in Bleeding Peptic Ulcer: A Randomized Clinical Trial. Full Text available with Trip Pro

High Dose versus Low Dose Intravenous Pantoprazole in Bleeding Peptic Ulcer: A Randomized Clinical Trial. BACKGROUND The appropriate dose of proton pump inhibitors for treatment of patients with upper (GI) bleeding remains controversial. This study compares high-dose versus low-dose intravenous proton pump inhibitor (PPI) infusion for prevention of GI bleeding complications. METHODS A total of 166 patients with bleeding peptic ulcers underwent therapeutic endoscopy using concomitant therapy (...) by argon plasma coagulation (APC) and diluted epinephrine injection. Patients were randomly divided into two groups: high-dose pantoprazole (80 mg bolus, 8 mg per hour) and low-dose pantoprazole (40 mg bolus, 4 mg per hour) infused for three days. Initial outcomes were rebleeding, need for surgery, hemoglobin drop more than two units, and hospitalization for more than five days. Secondary outcome included mortality rate. RESULTS Overall, 166 patients (83 patients per group) enrolled in the study

2014 Middle East journal of digestive diseases Controlled trial quality: uncertain

20. Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding. (Abstract)

Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding. Following successful endoscopic therapy in patients with peptic ulcer bleeding, rebleeding occurs in 4% to 30% of cases. Rebleeding remains the most important determinant of poor prognosis. The aim of our study is to compare the efficacy of intravenous pantoprazole and ranitidine for prevention of rebleeding of peptic ulcers following initial endoscopic hemostasis. In our study patients who had gastric (...) or duodenal ulcers with bleeding received combined endoscopy therapy with injection of epinephrine and thermocoagulation. Patients with initial hemostasis were randomly assigned to two groups. One group (45 patients) was treated with intravenous pantoprazole, with an initial dose of 40 mg and subsequently with 40 mg every twelve hours during the first three days, followed by 40 mg a day orally. The other group (44 patients) was treated with intravenous ranitidine, with an initial dose of 50 mg

2013 Georgian medical news Controlled trial quality: uncertain